Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study

NCT00869908 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00869908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00869908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
November 30, 2008
Completion date
March 31, 2011
Enrollment
66,726 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2